Sanofi links with Evotec to tap stem cells for diabetes care

(Reuters) – French drugmaker Sanofi is linking with Evotec to develop stem cell-based treatments for diabetes, under a deal that could earn the German biotech firm more than 300 million euros ($327 million). Sanofi, a leading supplier of diabetes care …

[Read the full article here]

Comments are closed.